Cohance Lifesciences shares fell around 7% after the company reported an 84% year-on-year drop in March-quarter net profit. Jefferies cut its target and downgraded the stock to Underperform, pointing to management instability and weak visibility into performance. Goldman Sachs kept a Buy rating, citing longer-term opportunities despite a rough near-term outlook.
Brokerages have started coverage on Meesho, Swiggy, and three other Indian stocks, spotlighting big upside potential. JP Morgan rates Meesho “Overweight” with about 11% upside, while Equirus gives Swiggy a “Buy” targeting roughly 48% gains. Analysts also turned constructive on Capillary Technologies, Shadowfax Technologies, and Shyam Metallics.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
